BPC-157 Research Literature

Few peptides have attracted as much sustained scientific interest as BPC-157. Originally isolated from human gastric juice, this 15-amino-acid peptide has been the subject of published research since 1993 — over three decades of studies spanning tendon repair, gut healing, tissue regeneration, and beyond.

A 2025 systematic review published in the American Journal of Sports Medicine examined 36 studies conducted between 1993 and 2024 and concluded that BPC-157 consistently improved healing outcomes across muscle, tendon, ligament, and bone injury models. That level of cross-tissue replication is unusual in peptide research and explains why BPC-157 remains one of the most studied compounds in its class.

The most extensive body of BPC-157 research focuses on connective tissue repair. Dr. Predrag Sikiric and his team at the University of Zagreb have published extensively on this compound since the early 1990s.

In a key study published in the Journal of Applied Physiology, researchers treated rat Achilles tendon cells with BPC-157 at concentrations of 0.5, 1, and 2 micrograms per milliliter for 24 hours. The results showed that BPC-157 significantly accelerated the migration of tendon fibroblasts — the cells responsible for building and repairing tendon tissue — in a dose-dependent manner. Higher concentrations produced faster cell migration.

The same study found that when tendon cells were exposed to oxidative stress (a common factor in injury), BPC-157-treated cells survived at significantly higher rates than untreated cells. The researchers observed clear morphological differences between treated and untreated groups under microscopy.

In a 2021 study published in Biomedicines, researchers investigated BPC-157 in rats with surgically separated quadriceps tendons — an injury model that does not heal on its own. Rats received either 10 micrograms per kilogram or 10 nanograms per kilogram of BPC-157, administered either by injection or orally in drinking water at 0.16 micrograms per milliliter over the course of 12 milliliters per day.

The results were striking. By day 28, treated rats showed complete disappearance of the tissue defect and full functional recovery, including restored walking patterns. Control animals showed no healing and progressive muscle wasting over the same period. The researchers documented these outcomes through imaging, microscopy, biomechanical testing, and functional walking assessments.

A 2014 study published in Molecules used microarray analysis to identify which genes BPC-157 activates in tendon cells. Researchers found that growth hormone receptor was one of the most significantly upregulated genes — showing a 2.29-fold increase in expression compared to untreated cells.

When the team then added growth hormone to BPC-157-treated cells, cell proliferation increased in both a dose-dependent and time-dependent manner. This suggests BPC-157 may enhance tissue repair partly by making cells more responsive to the body's own growth signals — a mechanism that had not been previously identified for this compound.

Beyond connective tissue, BPC-157 has been studied for its effects on gastrointestinal tissue — which makes sense given that it was originally discovered in gastric juice. Dr. Sikiric's research group has published studies showing protective effects in various gut injury models, including studies on inflammatory bowel conditions and stomach lining damage.

A 2018 review published in Current Pharmaceutical Design by Sikiric and colleagues examined the full breadth of BPC-157 preclinical evidence across injury models, noting consistent positive outcomes across gut, vascular, and musculoskeletal research.

The vast majority of BPC-157 research has been conducted in animal models; only a small number of human observations have been published. As one example, Vasireddi et al.'s 2025 systematic review noted a small, uncontrolled retrospective observation in which some individuals with chronic knee pain reported relief — the kind of preliminary signal that motivates trials, not a controlled efficacy finding.

A 2026 review in the International Journal of Molecular Sciences summarized the current state of human research, noting early studies investigating musculoskeletal pain, interstitial cystitis, and intravenous administration. The authors emphasized that this human work is preliminary and that formal large-scale clinical trials have not yet been completed.

Across published animal studies, researchers have generally reported that a specific toxic or lethal dose was not identified in their models, and several groups have cited this preclinical record as a reason to call for formal human clinical trials.

Important framing: this is animal and in-vitro data, not a safety assurance — findings in animal models do not establish human safety. BPC-157 has also been discussed in the context of angiogenic signaling, which is why any work involving subjects with active cancer or other serious disease is a question for a qualified clinician, not a research page. Regulatory note: the FDA placed BPC-157 in a category restricting compounding in 2024. This material is provided strictly for laboratory-research context.

BPC-157 is often studied alongside other tissue-repair compounds. TB-500 (Thymosin Beta-4) is another peptide researched for connective tissue applications, though its published literature focuses more on cardiac and dermal tissue models. GHK-Cu has been studied primarily in skin and wound healing contexts. BPC-157's research base is notably broader, spanning tendons, muscles, ligaments, bones, gut tissue, and vascular models — making it one of the most versatile compounds in published peptide research.